(Note: Altamont Pharma Acquisition Corp. withdrew its SPAC IPO prospectus in an SEC filing dated July 6, 2022. The S-1 was filed on March 23, 2021; the confidential IPO paperwork filing was on Feb. 12, 2021. Each unit consisted of one share of common stock and one warrant to buy one-half share of common stock.) 

It is our intention to pursue prospective targets that are focused on healthcare innovation. (Incorporated in Delaware)

We anticipate targeting companies located in North America or Europe that are developing assets in the biopharma and medical technology sectors, which aligns with our management team’s experience in healthcare investing and drug development.

Our sponsor is an affiliate of Altamont Pharmaceutical Holdings, LLC (“Altamont Pharma”) and JDH Investment Management, LLC (“JDH”), both of which have reputations as leading capital providers to healthcare industry entrepreneurs and academics due to their investment expertise, deep industry relationships, and knowledge in the sector.

We will be led by Mark Pearson, Chairman and Chief Executive Officer of Altamont Pharma, and advised by both John D. Harkey, Jr., Founder and Principal of JDH, and Jay Shepard. Mr. Pearson, Mr. Harkey and Mr. Shepard have more than 30 years of combined experience in healthcare investing across multiple sectors including but not limited to the addiction, pain, and neurological disorders of the Central Nervous System (“CNS”) space.

Members of our management team and board have been directly involved in many successful transactions as Co-Founders, Managers, and/or substantial investors including strategic sales like Nextwave Pharmaceuticals acquired by Pfizer (NYSE: PFE), Ilypsa acquired by Amgen (NASDAQ: AMGN), Replysa (NASDAQ: RLYP) acquired by Vifor Pharma (OTC: GNHAF), Stemcentryx acquired by AbbVie (NYSE: ABBV), AveXis (NASDAQ: AVXS) acquired by Novartis (NYSE: NVS) and CerSci Therapeutics acquired by Acadia Pharmaceuticals (NASDAQ: ACAD).

We believe that our company’s alignment with Altamont Pharma and JDH, and our ability to leverage the rigorous and comprehensive scientific and financial analysis that these firms are known for, provides us with a strong competitive advantage. Altamont Pharma and JDH focuses on identifying transformational innovations across the life sciences space, specifically backing scientific programs that have the potential to disrupt the current standard of care in their respective disease areas.

Altamont Pharma and JDH invest across the public/private spectrum, supporting rapidly growing biotech companies through multiple stages of their respective life cycles. To date, Altamont Pharma and JDH have successfully assisted companies through the U.S. Food and Drug Administration (“FDA”) approval process as well as aided in the commercialization of available drugs.